Market Research Logo

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2018

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2018, provides an overview of the Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes and bleeding.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 10 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Lassa Fever (Lassa Hemorrhagic Fever) - Overview
Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lassa Fever (Lassa Hemorrhagic Fever) - Companies Involved in Therapeutics Development
Celgene Corp
Etubics Corp
GeoVax Labs Inc
Inovio Pharmaceuticals Inc
Kineta Inc
Profectus BioSciences Inc
Lassa Fever (Lassa Hemorrhagic Fever) - Drug Profiles
CC-11050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GEOLM-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-1400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LHF-535 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ML-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Lassa Fever - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Lassa Fever - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-193 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects
Lassa Fever (Lassa Hemorrhagic Fever) - Product Development Milestones
Featured News & Press Releases
Oct 24, 2017: Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study
Jul 24, 2017: GeoVax Joins with Scripps Research Institute and Institute of Human Virology at University of Maryland School of Medicine to Develop Lassa Fever Vaccine
Jul 11, 2017: Tulane University awarded $12 million to create Lassa vaccine and treatment
Jul 10, 2017: GeoVax Reports Promising Results for Lassa Fever Vaccine
May 05, 2016: Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials
Apr 22, 2016: Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Celgene Corp, H1 2018
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Etubics Corp, H1 2018
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by GeoVax Labs Inc, H1 2018
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Kineta Inc, H1 2018
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Profectus BioSciences Inc, H1 2018
Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects, H1 2018
List of Figures
Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report